$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414067147 Filed on November 12, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$873.7K	$1.162M	$880.7K
YoY Change	-0.72%	31.98%	45.49%
Cost Of Revenue	$330.0K	$475.9K	$620.6K
YoY Change	-60.71%	-23.32%	337.52%
Gross Profit	$544.3K	$686.5K	$260.1K
YoY Change	1260.86%	163.95%	-43.89%
Gross Profit Margin	62.31%	59.06%	29.53%
Selling, General & Admin	$2.480M	$1.240M	$687.8K
YoY Change	145.54%	80.36%	91.25%
% of Gross Profit	455.6%	180.71%	264.46%
Research & Development	$970.0K	$880.3K	$294.2K
YoY Change	3133.33%	199.22%	-46.92%
% of Gross Profit	178.2%	128.24%	113.12%
Depreciation & Amortization	$0.00	$20.00K	$20.00K
YoY Change	-100.0%	0.0%	100.0%
% of Gross Profit	0.0%	2.91%	7.69%
Operating Expenses	$3.450M	$2.170M	$1.140M
YoY Change	231.73%	90.37%	7.07%
Operating Profit	-$2.892M	-$1.484M	-$879.8K
YoY Change	189.17%	68.62%	46.35%
Interest Expense	-$2.480M	-$46.60K	-$84.95K
YoY Change	1966.67%	-45.14%	67.21%
% of Operating Profit
Other Income/Expense, Net		-$14.80K	-$84.95K
YoY Change		-82.58%	67.21%
Pretax Income	-$5.380M	-$1.498M	-$964.8K
YoY Change	376.11%	55.3%	47.98%
Income Tax	-$390.0K
% Of Pretax Income
Net Earnings	-$4.990M	-$1.498M	-$964.8K
YoY Change	644.78%	55.3%	47.98%
Net Earnings / Revenue	-571.16%	-128.91%	-109.55%
Basic Earnings Per Share
Diluted Earnings Per Share	-$223.3K	-$120.0K	-$98.97K
COMMON SHARES
Basic Shares Outstanding	581.8M shares	310.7M shares	245.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.500M	$7.800M	$2.300M
YoY Change	150.0%	239.13%	9.52%
Cash & Equivalents	$3.605M	$433.4K	$2.350M
Short-Term Investments	$1.900M	$7.300M
Other Short-Term Assets	$700.0K	$200.0K	$700.0K
YoY Change	16.67%	-71.43%	600.0%
Inventory	$537.6K	$387.1K	$362.5K
Prepaid Expenses
Receivables	$819.2K	$600.0K	$200.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.607M	$8.954M	$3.644M
YoY Change	118.16%	145.73%	25.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$245.8K	$191.1K	$143.5K
YoY Change	70.24%	33.16%	43.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$615.8K	$481.0K	$251.4K
YoY Change	48.61%	91.33%	-16.2%
Total Long-Term Assets	$861.6K	$672.1K	$394.9K
YoY Change	54.2%	70.19%	-1.26%
TOTAL ASSETS
Total Short-Term Assets	$7.607M	$8.954M	$3.644M
Total Long-Term Assets	$861.6K	$672.1K	$394.9K
Total Assets	$8.469M	$9.627M	$4.039M
YoY Change	109.32%	138.34%	22.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$698.3K	$446.2K	$572.0K
YoY Change	-11.22%	-22.0%	-18.28%
Accrued Expenses	$800.0K	$400.0K	$500.0K
YoY Change	100.0%	-20.0%	25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$1.600M
YoY Change	-100.0%	-100.0%	60.0%
Total Short-Term Liabilities	$4.505M	$1.549M	$3.066M
YoY Change	47.0%	-49.46%	45.99%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.505M	$1.549M	$3.066M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.500M	$1.500M	$3.066M
YoY Change	46.82%	-51.07%	45.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$124.4M	-$113.9M
YoY Change	17.57%
Common Stock	$23.31K	$322.8K	$245.1K
YoY Change	131.82%	31.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.945M	-$10.80M	-$13.61M
YoY Change
Total Liabilities & Shareholders Equity	$8.469M	$9.627M	$4.039M
YoY Change	109.32%	138.34%	22.39%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$4.990M	-$1.498M	-$964.8K
YoY Change	644.78%	55.3%	47.98%
Depreciation, Depletion And Amortization	$0.00	$20.00K	$20.00K
YoY Change	-100.0%	0.0%	100.0%
Cash From Operating Activities	-$2.090M	-$1.930M	-$560.0K
YoY Change	90.0%	244.64%	-11.11%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$60.00K	-$10.00K
YoY Change	11.76%	500.0%	-200.0%
Acquisitions
YoY Change
Other Investing Activities	$5.410M	-$2.600M
YoY Change
Cash From Investing Activities	$5.220M	-$2.670M	-$10.00K
YoY Change	-3170.59%	26600.0%	-200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	180.0K	30.00K	1.010M
YoY Change	-84.75%	-97.03%	6.32%
NET CHANGE
Cash From Operating Activities	-2.090M	-1.930M	-560.0K
Cash From Investing Activities	5.220M	-2.670M	-10.00K
Cash From Financing Activities	180.0K	30.00K	1.010M
Net Change In Cash	3.310M	-4.570M	440.0K
YoY Change	-3777.78%	-1138.64%	33.33%
FREE CASH FLOW
Cash From Operating Activities	-$2.090M	-$1.930M	-$560.0K
Capital Expenditures	-$190.0K	-$60.00K	-$10.00K
Free Cash Flow	-$1.900M	-$1.870M	-$550.0K
YoY Change	104.3%	240.0%	-14.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3769819	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.13
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	8046000	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Granted In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantedInPeriodWeightedAverageGrantDateFairValue	0.058
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.83
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.044
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	55845283	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsGrantsInPeriod	16135000	shares
CY2014Q1	ctso	Agreement To Purchase Shares Value AgreementToPurchaseSharesValue	16575000	USD
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y1M6D
CY2013Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	9486720	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2013Q4	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.034
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.20
CY2014Q1	ctso	Subscription Agreement Offering Units SubscriptionAgreementOfferingUnits	40800000	shares
	ctso	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2014Q1	ctso	Agreement To Purchase Shares Value AgreementToPurchaseSharesValue	2762500	USD
CY2014Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10200000	USD
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeituresInPeriod	4861250	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.3125
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1123033	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Forfeited In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue	0.033
CY2014Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2451070	shares
CY2014Q1	ctso	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	0.25
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9451000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	16135000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.21
CY2014Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	41203791	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	51809	shares
CY2014Q3	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsWeightedAverageGrantDateFairValue	0.051
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	5695250	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20400000	shares
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	159000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.50
CY2013Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1098000	USD
CY2013Q4	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	13418000	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsVestedInPeriod	2412250	shares
CY2013	ctso	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	150000	USD
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2466300	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm	P7Y7M6D
CY2014Q1	ctso	Preferred Stock Conversion Percent Of Stated Value PreferredStockConversionPercentOfStatedValue	0.00	pure
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2466300	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	47923642	shares
CY2014Q3	ctso	Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue	791000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.20
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M6D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber	14010000	shares
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3022687	USD
CY2014Q3	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue	3552000	USD
CY2014Q3	ctso	Share Based Compensation Arrangement By Share Based Payment Award Nonvested Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedOptionsOutstandingNumber	22279500	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	180100	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	65468	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	70449	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	47573	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	198644	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	228468	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	150273	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	300105	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-208080	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	112183	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	142094	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	141467	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-319830	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-380308	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-318438	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4568	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-9442	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-109500	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38989	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-269026	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4188849	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2386815	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89495	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33276	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	89762	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18861	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7346994	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7526251	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52137	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	9751455	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	1599967	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	1263000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90855	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20194	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9842310	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	123183	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	36915	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1749607	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	620650	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2183030	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1729344	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2349994	USD
	ctso	Debt Discount DebtDiscount	331117	USD
	ctso	Fair Value Warranty Liability Upon Issuance FairValueWarrantyLiabilityUponIssuance	862920	USD
	us-gaap	Stock Issued1 StockIssued1	7137	USD
	us-gaap	Stock Issued1 StockIssued1	34034	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1990440	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1226042	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	748545	USD
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	3769819	USD
	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	1728053	USD
	ctso	Bad Debt Expense BadDebtExpense	3236	USD
	ctso	Bad Debt Expense BadDebtExpense		USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	435686	USD
CY2014Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1644356	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1549450	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3064932	USD
CY2013Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	361700	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3333	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	272359	USD
CY2014Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	654840	USD
CY2014Q3	ctso	Convertible Notes Current Unamortized Discount ConvertibleNotesCurrentUnamortizedDiscount	0	USD
CY2013Q4	ctso	Convertible Notes Current Unamortized Discount ConvertibleNotesCurrentUnamortizedDiscount	198644	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	139526	USD
	us-gaap	Interest Paid InterestPaid		USD
	us-gaap	Interest Paid InterestPaid		USD
	ctso	Debt Discount DebtDiscount		USD
	ctso	Fair Value Warranty Liability Upon Issuance FairValueWarrantyLiabilityUponIssuance		USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions		USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	580000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		USD
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	561964	USD
CY2013Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	453017	USD
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	7346994	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	387075	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	245608	USD
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	225004	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	605312	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	8954460	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3486967	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	191127	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	144393	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	481017	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	414375	USD
CY2014Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	672144	USD
CY2013Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	558768	USD
CY2014Q3	us-gaap	Assets Assets	9626604	USD
CY2013Q4	us-gaap	Assets Assets	4045735	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	446167	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	786517	USD
CY2014Q3	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	445110	USD
CY2014Q3	ctso	Preferred Stock Value Not Included In Stockholders Equity PreferredStockValueNotIncludedInStockholdersEquity	18874241	USD
CY2013Q4	ctso	Preferred Stock Value Not Included In Stockholders Equity PreferredStockValueNotIncludedInStockholdersEquity	15246350	USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	1895	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	1760	USD
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	322775473	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	251319547	shares
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	322775	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	251320	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102713676	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	91343135	USD
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	67196	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-55987	USD
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113902629	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105805775	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	107000	USD
CY2014Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	250000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	101000	USD
CY2014Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	36000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	38000	USD
	us-gaap	Advertising Expense AdvertisingExpense	94000	USD
	us-gaap	Advertising Expense AdvertisingExpense	30000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	77000	USD
	us-gaap	Shipping Handling And Transportation Costs ShippingHandlingAndTransportationCosts	17000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-10797087	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-14265547	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9626604	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4045735	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	433423	USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments		USD
CY2013Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent		USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3236	USD
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	322775473	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	251319547	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	101000	USD
CY2014Q3	ctso	Undesignated Preferred Stock Authorized UndesignatedPreferredStockAuthorized	100000000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>Use of Estimates</strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability, and valuation methods used in determining any debt discount associated with convertible securities.</p> </div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><strong>Concentration of Credit Risk</strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">As of September 30, 2014, <font>four</font> distributors, and <font>one</font> hospital accounted for approximately <font>64</font>% of outstanding grant and accounts receivable. At December 31, 2013, <font>one</font> U.S. government agency accounted for approximately <font>66</font>% of outstanding accounts receivable. For the nine months ended September 30, 2014, approximately <font>19</font>% of revenues were from <font>one</font> U.S. government agency, and <font>no</font> other agency, distributor, or direct customer represented more than <font>10</font>% of the Company's revenue. For the nine months ended September 30, 2013, approximately <font>67</font>% of revenues were from <font>two</font> U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.</p> </div>
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	180100	USD
	ctso	Dividends Preferred Stock Series B DividendsPreferredStockSeriesB	-3743536	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300000	USD
CY2014Q3	ctso	Number Of Patents Issued NumberOfPatentsIssued	32	pure
	ctso	Stock Issued During Period Value Offering StockIssuedDuringPeriodValueOffering	10200000	USD
	ctso	Issuance Of Common Stock In Exchange For Convertible Notes Value IssuanceOfCommonStockInExchangeForConvertibleNotesValue	1990440	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-748545	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	123183	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90855	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4327035	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock		USD
	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		USD
	ctso	Stock Issued During Period Value Conversion Of Units As Dividends StockIssuedDuringPeriodValueConversionOfUnitsAsDividends	115645	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1543505	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1162347	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	880692	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1804578	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1073689	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	475890	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	620623	USD
	us-gaap	Gross Profit GrossProfit	1444596	USD
	us-gaap	Gross Profit GrossProfit	469816	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	686457	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	260069	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1464059	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1706498	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	880292	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	294198	USD
	us-gaap	Professional Fees ProfessionalFees	733056	USD
	us-gaap	Professional Fees ProfessionalFees	570465	USD
CY2014Q3	us-gaap	Professional Fees ProfessionalFees	182996	USD
CY2013Q3	us-gaap	Professional Fees ProfessionalFees	157926	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3471138	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1901768	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1309519	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	687788	USD
	us-gaap	Operating Expenses OperatingExpenses	5668253	USD
	us-gaap	Operating Expenses OperatingExpenses	4178731	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	2372807	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	1139912	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4223657	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3708915	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1686350	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-879843	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-311458	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-299805	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-46600	USD
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-84946	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-234600	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-103378	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-299805	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	188000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-84946	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4327035	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4008720	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1498350	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-964789	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4008720	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1498350	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-964789	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1728053	USD
CY2014Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1281058	USD
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	525148	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8096854	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5736773	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2779408	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1489937	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	293189313	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	232426316	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	312400345	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	242512486	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	123183	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	36915	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	118032	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	40184	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4203852	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3971805	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1380318	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-924605	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet		USD
CY2013Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet		USD
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2264237	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	507628	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1031761	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	203561	USD
	us-gaap	Revenue From Grants RevenueFromGrants	978271	USD
	us-gaap	Revenue From Grants RevenueFromGrants	1035877	USD
CY2014Q3	us-gaap	Revenue From Grants RevenueFromGrants	128087	USD
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	677131	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	6666	USD
CY2014Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2499	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3249174	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	150273	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q3	us-gaap	Share Price SharePrice	0.224
CY2014Q1	us-gaap	Share Price SharePrice	0.240
CY2013Q3	ctso	Debt Instrument Percent Of Principal Amount DebtInstrumentPercentOfPrincipalAmount	0.50	pure
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.125
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20400000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20400000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.3125
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.3125
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.283	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.283	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0160	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0162	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y5M8D
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Basis Of Accounting BasisOfAccounting	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellpadding="0" cellspacing="0" style=" font: 10pt times new roman, times, serif; margin-top: 0; margin-bottom: 0;"> <tr style=" vertical-align: top; text-align: justify; font-size: 10pt;"><td style="width: 24px"> </td> <td style=" width: 0.25in; text-align: left; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"><font style=" font: 10pt Times New Roman, Times, Serif;"><strong><font>1</font>.</strong></font></td> <td style=" text-align: justify; border-left: none; border-right: none; border-top: none; border-bottom: none; font-size: 10pt;"><font style=" font: 10pt Times New Roman, Times, Serif;"><strong>BASIS OF PRESENTATION</strong></font></td> </tr> </table> </div> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the Commission) and include the results of CytoSorbents Corporation (the Parent), CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.), its wholly-owned operating subsidiary (the Subsidiary), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the European Subsidiary), collectively referred to as the Company.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company's accounts for the year ended December 31, 2014. In the opinion of the Company's management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company's consolidated financial position as of September 30, 2014 and the results of its operations and cash flows for the <font>nine</font> and <font>three</font> month periods ended September 30, 2014 and <font>2013</font>. Results for the nine months ended September 30, 2014 and <font>2013</font> are not necessarily indicative of results that may be expected for the entire year. The unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2013 as included in the Company's Form 10-K filed with the Commission on March 31, 2014.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future offerings to fund its research, development and commercialization program. The Company currently has adequate funding for more than the next twelve months of operations; however, it may have to raise additional capital to fund future operations. Although the Company has historically been successful in raising additional capital through equity and debt offerings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. Furthermore, if the Company is successful in raising the additional offering, there can be no assurance that the amount will be sufficient to complete the Company's plans. These matters raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Since inception, the Company's expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance and operational strategic planning. Although the Company has made advances on these matters, there can be <font>no</font> assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.</p> </div>
CY2013	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	1843000	USD
CY2013Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1511883	USD
CY2013Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	171012	USD
CY2013	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	160105	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	199000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	228000	USD
CY2013Q2	ctso	Debt Instrument Maturity Period DebtInstrumentMaturityPeriod	P1Y
CY2013Q3	ctso	Debt Instrument Maturity Period DebtInstrumentMaturityPeriod	P1Y
	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	581820005	shares
CY2013Q2	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.08	pure
CY2013Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.125
CY2013Q2	ctso	Debt Instrument Percent Of Principal Amount DebtInstrumentPercentOfPrincipalAmount	0.50	pure
CY2013Q2	ctso	Warrant Exercise Price WarrantExercisePrice	0.15
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	745000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.08	pure
CY2013Q3	ctso	Warrant Exercise Price WarrantExercisePrice	0.10

Files In Submission

Name	View Source	Status
0001144204-14-067147-index-headers.html	Edgar Link	pending
0001144204-14-067147-index.html	Edgar Link	pending
0001144204-14-067147.txt	Edgar Link	pending
0001144204-14-067147-xbrl.zip	Edgar Link	pending
ctso-20140930.xml	Edgar Link	completed
ctso-20140930.xsd	Edgar Link	pending
ctso-20140930_cal.xml	Edgar Link	unprocessable
ctso-20140930_def.xml	Edgar Link	unprocessable
ctso-20140930_lab.xml	Edgar Link	unprocessable
ctso-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v393032_10-q.htm	Edgar Link	pending
v393032_ex31-1.htm	Edgar Link	pending
v393032_ex31-2.htm	Edgar Link	pending
v393032_ex32-1.htm	Edgar Link	pending
v393032_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2014 Q4 Form 10-Q Financial Statement

#000114420414067147 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2014 Q4 Form 10-Q Financial Statement

#000114420414067147 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso